NCT03748745View on ClinicalTrials.gov

A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 19, 2018

Primary Completion Date

December 25, 2018

Study Completion Date

December 25, 2018

Conditions

Drug Interactions

Interventions

DRUG

SH229

tablet, oral, 600 mg once daily for day 1 to day 14

DRUG

SH229

tablet, oral, 600 mg once daily for day 8 to day 14

DRUG

Daclatasvir dihydrochloride

tablet, oral, 60 mg once daily for day 8 to day 14

DRUG

Daclatasvir dihydrochloride

tablet, oral, 60 mg once daily for day 1 to day 14

Trial Locations (1)

130000

Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun

All Listed Sponsors

lead

Nanjing Sanhome Pharmaceutical, Co., Ltd.

INDUSTRY

NCT03748745 - A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects | Biotech Hunter | Biotech Hunter